NO20015298L - Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne - Google Patents

Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne

Info

Publication number
NO20015298L
NO20015298L NO20015298A NO20015298A NO20015298L NO 20015298 L NO20015298 L NO 20015298L NO 20015298 A NO20015298 A NO 20015298A NO 20015298 A NO20015298 A NO 20015298A NO 20015298 L NO20015298 L NO 20015298L
Authority
NO
Norway
Prior art keywords
glp
ischemic
improve
function
biologically active
Prior art date
Application number
NO20015298A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015298D0 (no
Inventor
Thomas R Coolidge
Mario R W Ehlers
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Publication of NO20015298D0 publication Critical patent/NO20015298D0/no
Publication of NO20015298L publication Critical patent/NO20015298L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20015298A 1999-04-30 2001-10-29 Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne NO20015298L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/303,016 US6429197B1 (en) 1998-10-08 1999-04-30 Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
PCT/US2000/011652 WO2000066142A2 (en) 1999-04-30 2000-05-01 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Publications (2)

Publication Number Publication Date
NO20015298D0 NO20015298D0 (no) 2001-10-29
NO20015298L true NO20015298L (no) 2001-12-28

Family

ID=23170209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015298A NO20015298L (no) 1999-04-30 2001-10-29 Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne

Country Status (14)

Country Link
US (2) US6429197B1 (de)
EP (1) EP1187628B1 (de)
JP (1) JP2002543145A (de)
CN (1) CN1376072A (de)
AT (1) ATE369873T1 (de)
AU (2) AU774084B2 (de)
CA (1) CA2368772C (de)
DE (1) DE60035987T2 (de)
ES (1) ES2290029T3 (de)
IL (1) IL145829A0 (de)
MX (1) MXPA01010937A (de)
NO (1) NO20015298L (de)
NZ (1) NZ514609A (de)
WO (1) WO2000066142A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
EP1282436B1 (de) * 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Behandlung des akuten koronaren syndroms mit glp-1
PT1294757E (pt) * 2000-06-16 2007-02-28 Lilly Co Eli Análogos do peptídeo-1 do tipo glucagon
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
ATE408414T1 (de) * 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004071393A2 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
EP1617888B1 (de) 2003-04-23 2019-06-12 Valeritas, Inc. Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
WO2005060986A1 (en) * 2003-12-12 2005-07-07 Albert Einstein College Of Medicine Of Yeshiva University Glp-1 (9-36) methods and compositions
US20080194483A1 (en) * 2003-12-12 2008-08-14 Brownlee Michael A GLP-1 (9-36) methods and compositions
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
ES2656675T3 (es) 2006-03-30 2018-02-28 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2010013012A2 (en) * 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8641671B2 (en) 2009-07-30 2014-02-04 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN101706297B (zh) * 2009-08-10 2012-10-17 浙江鼎立实业有限公司 数显式微压和微流量综合检测台
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
CN103566354B (zh) * 2012-07-25 2017-12-05 江苏豪森药业集团有限公司 含有glp‑1类似物的衍生物或其可药用盐的药物组合物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902919B (zh) 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102449167B1 (ko) * 2016-05-06 2022-09-28 파세비오 파마수티컬스 인코포레이티드 제어된 지속 방출을 위한 elp 융합 단백질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5373016A (en) 1993-05-28 1994-12-13 Zeneca, Inc. Protection of isothiazolinone biocides from free radicals
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
AU6586298A (en) * 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
MXPA02006118A (es) 2000-10-20 2004-08-23 Amylin Pharmaceuticals Inc Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.

Also Published As

Publication number Publication date
USRE41288E1 (en) 2010-04-27
CA2368772A1 (en) 2000-11-09
US6429197B1 (en) 2002-08-06
MXPA01010937A (es) 2002-05-06
AU2004212547B2 (en) 2008-03-20
DE60035987D1 (de) 2007-09-27
IL145829A0 (en) 2002-07-25
NO20015298D0 (no) 2001-10-29
AU4682500A (en) 2000-11-17
EP1187628B1 (de) 2007-08-15
JP2002543145A (ja) 2002-12-17
DE60035987T2 (de) 2008-05-08
WO2000066142A2 (en) 2000-11-09
ES2290029T3 (es) 2008-02-16
CA2368772C (en) 2011-11-15
CN1376072A (zh) 2002-10-23
EP1187628A2 (de) 2002-03-20
ATE369873T1 (de) 2007-09-15
AU774084B2 (en) 2004-06-17
AU2004212547A1 (en) 2004-10-14
WO2000066142A3 (en) 2002-01-24
NZ514609A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
NO20015298L (no) Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
EA200501422A1 (ru) Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
CA2395165A1 (en) Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
NO20015294L (no) Metabolsk intervensjon med GLP-1 for å forbedre funksjonen av iskemisk og reperfundert vev
EP1425031B8 (de) High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
EA200400658A1 (ru) Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)
MXPA03002160A (es) Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
HK1052139B (zh) 治療腺病毒眼感染的方法和組合物
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
RU2003113987A (ru) Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны
EA199901103A1 (ru) Антивирусный препарат для инъекций
ECSP982542A (es) Nuevo metodo de tratamiento iii
CO5150158A1 (es) Tratamiento antidiabetico novedoso
RU2013142835A (ru) Способ лечения ишемического инсульта
RU2003138011A (ru) Способ лечения хронического пиелонефрита
RU2000104444A (ru) Способ лечения больных с аменореей центрального генеза
ECSP982541A (es) Nuevo metodo de tratamiento ii
DE60306344D1 (de) Behandlung von typ i diabetes mellitus mit wachstumshormonantagonisten
ECSP982591A (es) Nuevo metodo de tratamiento iv
UA116600U (uk) Спосіб лікування гострого ішемічного інсульту

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application